Drug Trial Radar · NCT06462313
Dobutamine for Management of Surgical Patients With Septic Shock
Last checked: Nov 19, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
584
Actual
Start
Jun 18, 2024
Primary completion
Nov 15, 2025
Study completion Nov 15, 2025
Sponsor
- Lead sponsor
- First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ningbo No. 1 Hospital; Lishui Country People's Hospital; The Central Hospital of Lishui City; Zhejiang Provincial Tongde Hospital; Ningbo No.2 Hospital; Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University; The First Affiliated Hospital of Zhengzhou University; Zunyi Medical College; The Second Hospital of Hebei Medical University; Affiliated Hospital of Jiaxing University; First Affiliated Hospital of Xinjiang Medical University; The First Affiliated Hospital of Anhui Medical University; Huaibei Peolple's Hospital; Anqing Municipal Hospital; The Second Hospital University of South China; The First Affiliated Hospital of University of South China; Wenzhou people's hospital,zhejiang province,China; People's Hospital of Xinjiang Uygur Autonomous Region; The First Clinical College of Harbin University; The First Affiliated Hospital of Shihezi University; Weifang People's Hospital; Tianjin Medical University General Hospital; Central Hospital of Heng Yang; First Affiliated Hospital of Shenzhen University; Henan Provincial People's Hospital; Southwest Hospital, China; The First People's Hospital of Zunyi; Affiliated Hospital of Guangdong Medical University; Union hospital of Fujian Medical University; Zhejiang Provincial People's Hospital; Red Cross Hospital, Hangzhou, China; Weihai Municipal Hospital; The First Affiliated Hospital of Soochow University; Zhejiang Cancer Hospital; Renmin Hospital of Wuhan University; Wuhan Third Hospital; Tongji Hospital; Zhujiang Hospital; Fuyang Hospital of Anhui Medical University; The Hospital of Suixi County; Fujian Provincial Hospital; Guizhou Provincial People's Hospital
- First posted
- Jun 17, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Septic shock is the last and most severe stage of sepsis and is defined by extremely low blood pressure, despite lots of intravenous fluids. The incidence of septic shock related cardiomyopathy was 10% to 70%. Besides, general anesthesia will inhibit the sympathetic nervous system, reduce myocardial contractility and aggravate cardiac dysfunction. No randomized controlled trials have yet explore the effects of dobutamine on clinical outcomes for patients with septic shock undergoing surgery under general anesthesia.
Conditions
- Patients With Septic Shock
- Surgical Patients
- General Anesthesia
Interventions
DobutamineDrug
Patients with septic shock in Dobutamine group will be initiated on Dobutamine at 5 mcg/kg/min when electrocardiogram, invasive blood pressure, and oxygen saturation were monitored.
NorepinephrineDrug
Norepinephrine was titrated to maintain a mean arterial pressure at 65mmHg or more in both groups.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of acute kidney injury after surgeryTime frame: within 1 week after surgery
- Sequential Organ Failure Assessment (SOFA) scoreTime frame: Day 1 Day 3 and Day 7 in ICU after surgery
- MortalityTime frame: in hospital and Day 28 and Day 90 after the surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.